$ATRA
Atara Biotherapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024095533 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $40.19M $28.64M
YoY Change 1779.79% 2892.69%
Cost Of Revenue $7.602M $4.627M
YoY Change 190.15% 59.83%
Gross Profit $32.59M $24.01M
YoY Change -6889.17% -1339.06%
Gross Profit Margin 81.08% 83.84%
Selling, General & Admin $10.42M $8.912M
YoY Change -14.93% -33.17%
% of Gross Profit 31.98% 37.11%
Research & Development $43.92M $33.33M
YoY Change -22.79% -40.63%
% of Gross Profit 134.79% 138.81%
Depreciation & Amortization $600.0K $700.0K
YoY Change -33.33% -22.22%
% of Gross Profit 1.84% 2.92%
Operating Expenses $43.92M $33.33M
YoY Change -22.79% -53.94%
Operating Profit -$21.76M -$18.23M
YoY Change -68.75% -74.47%
Interest Expense $1.183M $1.262M
YoY Change -15.2% -8.42%
% of Operating Profit
Other Income/Expense, Net $555.0K -$6.000K
YoY Change -2155.56% -40.0%
Pretax Income -$21.93M -$19.05M
YoY Change -68.59% -73.21%
Income Tax -$17.00K $0.00
% Of Pretax Income
Net Earnings -$21.91M -$19.05M
YoY Change -68.61% -73.21%
Net Earnings / Revenue -54.51% -66.51%
Basic Earnings Per Share -$2.93 -$3.10
Diluted Earnings Per Share -$2.93 -$3.10
COMMON SHARES
Basic Shares Outstanding 4.915M 120.4M
Diluted Shares Outstanding 7.466M 6.143M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.19M $35.29M
YoY Change -34.39% -77.03%
Cash & Equivalents $46.45M $31.31M
Short-Term Investments $20.74M $3.978M
Other Short-Term Assets $9.205M $5.801M
YoY Change -1.95% -42.93%
Inventory $13.98M $18.75M
Prepaid Expenses
Receivables $1.335M $2.422M
Other Receivables $0.00 $0.00
Total Short-Term Assets $91.86M $62.41M
YoY Change -22.61% -63.78%
LONG-TERM ASSETS
Property, Plant & Equipment $1.661M $2.317M
YoY Change -64.11% -56.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.357M $3.609M
YoY Change -46.62% -45.11%
Total Long-Term Assets $50.85M $54.87M
YoY Change -27.45% -25.97%
TOTAL ASSETS
Total Short-Term Assets $91.86M $62.41M
Total Long-Term Assets $50.85M $54.87M
Total Assets $142.7M $117.3M
YoY Change -24.41% -52.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.146M $5.253M
YoY Change -67.04% 26.95%
Accrued Expenses $8.059M $11.19M
YoY Change -2.89% 5.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.006M $975.0K
YoY Change 11.78% 13.5%
Total Short-Term Liabilities $156.0M $148.3M
YoY Change 97.22% 98.88%
LONG-TERM LIABILITIES
Long-Term Debt $37.58M $36.45M
YoY Change
Other Long-Term Liabilities $3.969M $4.167M
YoY Change -18.13% -17.04%
Total Long-Term Liabilities $3.969M $4.167M
YoY Change -18.13% -17.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $156.0M $148.3M
Total Long-Term Liabilities $3.969M $4.167M
Total Liabilities $233.2M $228.2M
YoY Change -2.66% -4.53%
SHAREHOLDERS EQUITY
Retained Earnings -$2.042B -$2.020B
YoY Change 6.98% 9.85%
Common Stock $1.951B $1.909B
YoY Change 5.0% 3.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$90.54M -$110.9M
YoY Change
Total Liabilities & Shareholders Equity $142.7M $117.3M
YoY Change -24.41% -52.41%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$21.91M -$19.05M
YoY Change -68.61% -73.21%
Depreciation, Depletion And Amortization $600.0K $700.0K
YoY Change -33.33% -22.22%
Cash From Operating Activities -$3.989M -$10.65M
YoY Change -92.23% -79.84%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $29.00K
YoY Change -100.0% -94.19%
Acquisitions
YoY Change
Other Investing Activities -$16.67M $7.225M
YoY Change -123.56% -85.54%
Cash From Investing Activities -$16.67M $7.196M
YoY Change -123.66% -85.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 35.79M -324.0K
YoY Change -17144.29% -168.79%
NET CHANGE
Cash From Operating Activities -3.989M -10.65M
Cash From Investing Activities -16.67M 7.196M
Cash From Financing Activities 35.79M -324.0K
Net Change In Cash 15.14M -3.773M
YoY Change -19.86% 32.71%
FREE CASH FLOW
Cash From Operating Activities -$3.989M -$10.65M
Capital Expenditures $0.00 $29.00K
Free Cash Flow -$3.989M -$10.67M
YoY Change -92.27% -79.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001604464
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36548
dei Entity Registrant Name
EntityRegistrantName
ATARA BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0920988
dei Entity Address Address Line1
EntityAddressAddressLine1
2380 Conejo Spectrum Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Thousand Oaks
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91320
dei City Area Code
CityAreaCode
805
dei Local Phone Number
LocalPhoneNumber
623-4211
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ATRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4915049
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31314000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25841000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
3978000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
25884000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2422000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34108000
CY2024Q2 us-gaap Inventory Net
InventoryNet
18749000
CY2023Q4 us-gaap Inventory Net
InventoryNet
9706000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
5801000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6184000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
62410000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
101869000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2317000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3856000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
48948000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54935000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3609000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4844000
CY2024Q2 us-gaap Assets
Assets
117284000
CY2023Q4 us-gaap Assets
Assets
165504000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5253000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3684000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7269000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11519000
CY2024Q2 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2014000
CY2023Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
17364000
CY2024Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
107582000
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
77833000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26149000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
31826000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
148267000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
142226000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
567000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
37562000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38703000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45693000
CY2024Q2 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
36448000
CY2023Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
34623000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4167000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4631000
CY2024Q2 us-gaap Liabilities
Liabilities
228152000
CY2023Q4 us-gaap Liabilities
Liabilities
264735000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4904000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4904000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4258000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4258000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1909097000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1870123000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-204000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2019951000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1969150000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-110868000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-99231000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117284000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165504000
CY2024Q2 atra Commercialization Revenue
CommercializationRevenue
28640000
CY2023Q2 atra Commercialization Revenue
CommercializationRevenue
793000
atra Commercialization Revenue
CommercializationRevenue
55997000
atra Commercialization Revenue
CommercializationRevenue
1677000
CY2024Q2 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
0
CY2023Q2 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
164000
atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
0
atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
506000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
28640000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
957000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
55997000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2183000
CY2024Q2 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
4627000
CY2023Q2 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
2895000
atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
6612000
atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
3111000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33332000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56141000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78838000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118297000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8912000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13335000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20025000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27207000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
46871000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
72371000
us-gaap Costs And Expenses
CostsAndExpenses
105475000
us-gaap Costs And Expenses
CostsAndExpenses
148615000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18231000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-71414000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49478000
us-gaap Operating Income Loss
OperatingIncomeLoss
-146432000
CY2024Q2 us-gaap Interest Income Operating
InterestIncomeOperating
450000
CY2023Q2 us-gaap Interest Income Operating
InterestIncomeOperating
1695000
us-gaap Interest Income Operating
InterestIncomeOperating
1054000
us-gaap Interest Income Operating
InterestIncomeOperating
3497000
CY2024Q2 us-gaap Interest Expense
InterestExpense
1262000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1378000
us-gaap Interest Expense
InterestExpense
2415000
us-gaap Interest Expense
InterestExpense
2714000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
62000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-207000
CY2024Q2 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
-818000
CY2023Q2 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
307000
atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
-1299000
atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
576000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19049000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-71107000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50777000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-145856000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-19049000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-71108000
us-gaap Net Income Loss
NetIncomeLoss
-50801000
us-gaap Net Income Loss
NetIncomeLoss
-145879000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
304000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
190000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1134000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19008000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70804000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50611000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-144745000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.1
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.1
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.91
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-34.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-34.89
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6143000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6143000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4204000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4204000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5883000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5883000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4181000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4181000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-99231000
CY2024Q1 atra Issuance Of Pre Funded Warrants Net Of Offering Costs
IssuanceOfPreFundedWarrantsNetOfOfferingCosts
177000
CY2024Q1 atra Issuance Of Pre Funded Warrants Registered Direct Offering Value
IssuanceOfPreFundedWarrantsRegisteredDirectOfferingValue
14823000
CY2024Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
9312000
CY2024Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
6000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8397000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31752000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
149000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-98308000
CY2024Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1000
CY2024Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
113000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6336000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-19049000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-110868000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
CY2023Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
590000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
93000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11764000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-74771000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
830000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
64960000
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1000
CY2023Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
747000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12552000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-71108000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
304000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7454000
us-gaap Profit Loss
ProfitLoss
-50801000
us-gaap Profit Loss
ProfitLoss
-145879000
us-gaap Share Based Compensation
ShareBasedCompensation
14733000
us-gaap Share Based Compensation
ShareBasedCompensation
24316000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2721000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2415000
us-gaap Accretion Expense
AccretionExpense
2093000
us-gaap Accretion Expense
AccretionExpense
2456000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-27000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1106000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
5987000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
5827000
atra Other Non Cash Items Net
OtherNonCashItemsNet
99000
atra Other Non Cash Items Net
OtherNonCashItemsNet
100000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-31686000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-39714000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9043000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6275000
atra Increase Decrease In Other Current Asset
IncreaseDecreaseInOtherCurrentAsset
-269000
atra Increase Decrease In Other Current Asset
IncreaseDecreaseInOtherCurrentAsset
-169000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-68000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
110000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1573000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2780000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4250000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-5103000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-15350000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-4255000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-7592000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
3685000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7246000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2514000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-5231000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-7021000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
108000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40257000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91225000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
83647000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
22069000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
128020000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
156000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
898000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21913000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43475000
atra Proceeds From Sale Of Pre Funded Warrants To Purchase Common Stock In A Registered Direct Offering Net
ProceedsFromSaleOfPreFundedWarrantsToPurchaseCommonStockInARegisteredDirectOfferingNet
14823000
atra Proceeds From Sale Of Pre Funded Warrants To Purchase Common Stock In A Registered Direct Offering Net
ProceedsFromSaleOfPreFundedWarrantsToPurchaseCommonStockInARegisteredDirectOfferingNet
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9348000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
590000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
113000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
747000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
94000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
460000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
524000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-7000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-13000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23817000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
706000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5473000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-47044000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25987000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31460000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46044000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
108000
us-gaap Interest Paid Net
InterestPaidNet
359000
us-gaap Interest Paid Net
InterestPaidNet
218000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
24000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, accrued research and development expenses, stock-based compensation expense, income taxes and the liability related to the sale of future revenues. Actual results could differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
832233
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
935273
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
34329000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
34315000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
50393000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
50189000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
34329000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
34315000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
50393000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50189000
CY2024Q2 us-gaap Interest Receivable
InterestReceivable
100000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
300000
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2024Q2 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2023Q2 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31314000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25841000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31460000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25987000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
20800000
CY2023Q4 atra Liability Related To Sale Of Future Revenues
LiabilityRelatedToSaleOfFutureRevenues
35076000
us-gaap Accretion Expense
AccretionExpense
2093000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
34000
us-gaap Payments For Royalties
PaymentsForRoyalties
71000
CY2024Q2 atra Liability Related To Sale Of Future Revenues
LiabilityRelatedToSaleOfFutureRevenues
37132000
CY2024Q2 atra Liability Related To The Sale Of Future Revenue Current
LiabilityRelatedToTheSaleOfFutureRevenueCurrent
684000
CY2024Q2 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
36448000
CY2023Q4 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.30
CY2023Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
6700000
CY2024Q2 atra Restructuring Liability Nov2023
RestructuringLiabilityNov2023
100000
CY2024Q1 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.25
CY2024Q1 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
5100000
CY2024Q2 atra Restructuring Liability Jan2024
RestructuringLiabilityJan2024
800000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
356000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
5107000
us-gaap Restructuring Charges
RestructuringCharges
45000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
4923000
us-gaap Restructuring Charges
RestructuringCharges
5107000
us-gaap Payments For Restructuring
PaymentsForRestructuring
8533000
atra Non Cash Settlements
NonCashSettlements
-613000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
884000
CY2024Q2 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2023Q4 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2024Q2 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2023Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2024Q2 atra Minimum Commitments Expense
MinimumCommitmentsExpense
3200000
atra Minimum Commitments Expense
MinimumCommitmentsExpense
6700000
CY2023Q2 atra Minimum Commitments Expense
MinimumCommitmentsExpense
3800000
atra Minimum Commitments Expense
MinimumCommitmentsExpense
13300000
CY2024Q2 atra Minimum Purchase Commitments Accrued
MinimumPurchaseCommitmentsAccrued
2500000
CY2023Q4 atra Minimum Purchase Commitments Accrued
MinimumPurchaseCommitmentsAccrued
11200000
CY2024Q2 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2023Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2024Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2023Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 atra Common Stock Value Remained Available To Be Sold
CommonStockValueRemainedAvailableToBeSold
88700000
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1329324
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6336000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12552000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14733000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24316000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
3642000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2335000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
15107000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
7371000
CY2024Q2 us-gaap Inventory Net
InventoryNet
18749000
CY2023Q4 us-gaap Inventory Net
InventoryNet
9706000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19719000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19725000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17402000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15869000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2317000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3856000
CY2024Q2 us-gaap Depreciation
Depreciation
700000
CY2023Q2 us-gaap Depreciation
Depreciation
900000
us-gaap Depreciation
Depreciation
1600000
us-gaap Depreciation
Depreciation
1800000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11187000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19007000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13024000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11264000
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
975000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
915000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
963000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
640000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26149000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
31826000
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-095533-index-headers.html Edgar Link pending
0000950170-24-095533-index.html Edgar Link pending
0000950170-24-095533.txt Edgar Link pending
0000950170-24-095533-xbrl.zip Edgar Link pending
atra-20240630.htm Edgar Link pending
atra-20240630.xsd Edgar Link pending
atra-ex10_1.htm Edgar Link pending
atra-ex10_2.htm Edgar Link pending
atra-ex31_1.htm Edgar Link pending
atra-ex31_2.htm Edgar Link pending
atra-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
atra-20240630_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending